|Targets||Ribosomal S6 Kinase (RSK)|
|Description||FMK is a potent, highly specific and irreversible ribosomal s6 kinase (RSK) inhibitor that covalently modifies the C-terminal kinase domain of RSK. Its IC50 value is 15 nM. It could prevent the activation of the N-terminal kinase domain of RSK by the C-terminal kinase domain, but does not affect the activity of the N-terminal domain. It binds in the CTKD ATP-binding site and inhibits RSK autophosphorylation at Ser386. It induces significant apoptosis in human FGFR3-expressing, t(4;14)-positive multiple myeloma cells. It is used to determine the role of RSK as a direct regulator of NHE1 phosphorylation and sarcolemmal NHE activity in this cell type, in response to 1-adrenergic stimulation.|
|Appearance||White to off-white solid|
|Synonyms||1-[4-Amino-7-(3-hydroxypropyl)-5-(4-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-2-fluoroethanone;RSK2 kinase inhibitor|
|Solubility||10 mM in DMSO|
|Application||FMK could prevent the activation of the N-terminal kinase domain of RSK by the C-terminal kinase domain, but does not affect the activity of the N-terminal domain. It is used to determine the role of RSK as a direct regulator of NHE1 phosphorylation and sarcolemmal NHE activity in this cell type, in response to 1-adrenergic stimulation.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||633.3±55.0 °C | Condition: Press: 760 Torr|
|Density||1.36±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
FMK is a potent, highly specific and irreversible ribosomal s6 kinase (RSK) inhibitor that covalently modifies the C-terminal kinase domain of RSK. Its IC50 val...
BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM, respectively; 10- to 100-fold selectivity for RSK t...
LJI308 is a RSK inhibitor. LJI308 overcomes chemoresistance by eliminating cancer stem cells. LJI308 targets the CSC population and repress TNBC growth and diss...
DG2 is a potent and selective inhibitor of p70 ribosomal S6 kinase 1 (S6K1) (IC50 = 9.1 nM) with ATP-competitive and cell-permeable properties.
Pluripotin, also known as SC-1, is a potent and selective activator of murine embryonic stem (ES) cell self-renewal. Pluripotin works through dual inhibition of...
PF-4708671 is a novel cell-permeable inhibitor of S6K1. PF-4708671 specifically inhibits the S6K1 isoform with a Ki of 20 nM and IC50 of 160 nM. PF-4708671 pre...
BIX 02565, a RSK2 inhibitor, has also been found to significanltly influence sorts of adrenergic receptor subtypes involved in ascular tone and cardiac function...
The hydrochloride salt form of LY2584702 which is a selective ATP competitive inhibitor of p70 S6 kinase. LY2584702 is still under Phase I trial for evaluating ...
CMK is a RSK2 kinase inhibitor. Its IC50 value for Cdc5(L158G) is 36 nM. It is used in the preparation of serine/threonine kinase inhibitors.
LY2584702 is an orally available inhibitor of p70S6K signaling, with potential antineoplastic activity.
LJH685, binding to the RSK2 N-terminal kinase ATP-binding site, is a potent inhibitor that specificlly targets RSK with antiproliferative effects in MAPK pathwa...
LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.